Akèy › Kansè tete negatif triple › Ohio
Etid klinik pou Kansè tete negatif triple nan Ohio
29 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05422794Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027), Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Cleveland Clinic - Mercy Hospital ( Site 0057), Canton
- Tri-County Hematology & Oncology Associates, Inc. ( Site 0076), Massillon
- Taylor Cancer Research Center ( Site 9500), Maumee
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Local Institution - 0102, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06618287First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care, Inc., Cincinnati
- Ohio State University CRS, Columbus
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT03606967A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- University of Cincinnati Medical Center, Cincinnati
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- The Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT05985655SMP-3124LP in Adults With Advanced Solid Tumors
- Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06526819Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05208762Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
- MetroHealth, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Jun 29, 2026 · NCT05677802A Study of LY4175408 in Participants With Advanced Cancer
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT07046923I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Cleveland Clinic, Cleveland
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- The Christ Hospital Cancer Center, Cincinnati
- Ohio State University Medical Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 29, 2026 · NCT04468061Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekrite
Laj 40 a 65 · Fanm · Mizajou Dec 11, 2025 · NCT06582615A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- The Christ Hospital, Cincinnati
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT05902988Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 29, 2025 · NCT06249048A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- The Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT06682793A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Gabrail Cancer Center Research, Canton
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 19, 2025 · NCT06568692A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Gabrail Cancer Center, Canton
Ap rekriteFaz 3
Laj 18 a 65 · Fanm · Mizajou Mar 21, 2025 · NCT03671044Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.